Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pan-tumor rollover study for long-term treatment and follow-up after BMS nivolumab parent trials
2018-004362-34Phase 2Active
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in cancer, Nonhematologic neoplasms and hematopoietic malignancies, sponsored by Bristol Myers Squibb. Primary endpoint: Incidence of adverse events. Started Nov 2019; status: active.
02
Drugs
03
Conditions
cancerNonhematologic neoplasmshematopoietic malignancies
Beyond the preview
Go deeper on 2018-004362-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004362-34.